See Editorial on Page 1881
Steatohepatitis/Metabolic Liver Disease
Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Version of Record online: 29 OCT 2013
© 2013 by the American Association for the Study of Liver Diseases
Volume 58, Issue 6, pages 1941–1952, December 2013
How to Cite
Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., Ratziu, V., Cariou, B. and Hanf, R. (2013), Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology, 58: 1941–1952. doi: 10.1002/hep.26461
Potential conflict of interest: B.S., V.R., and B.C. are consultants for Genfit.
Study supported by Genfit SA and an FP7/2007-2013 no. 305707 (RESOLVE) grant to B.S. B.S., M.B., A.L., and A.T. also received funding from Inserm and Université Lille 2. B.S. is a member of the Institut Universitaire de France.
- Issue online: 26 NOV 2013
- Version of Record online: 29 OCT 2013
- Accepted manuscript online: 22 MAY 2013 11:07AM EST
- Manuscript Accepted: 10 APR 2013
- Manuscript Revised: 11 MAR 2013
- Manuscript Received: 23 AUG 2012
Additional Supporting Information may be found in the online version of this article.
|hep26461-sup-0001-suppfig1.TIF||349K||Supporting Information Figure 1: Tissue distribution (A) and enterohepatic cycling (B) of GFT505.|
|hep26461-sup-0002-suppfig2.TIF||572K||Supporting Information Figure 2: Effects of fenofibrate on metabolic parameters and liver histology in hApoE2-KI and hApoE2-KI/PPARα-KO mice fed a western diet.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.